Short answer
Viridian Therapeutics, Inc.\DE (VRDN) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $284,000 (up 278.7% year over year) with net income of −$127M.
Q2 2026 key financials · XBRL
- Revenue
- $284,000
- +278.7% YoY · +101.4% QoQ
- Net income
- −$127M
- −26.2% YoY · −21.2% QoQ
- Operating margin
- -44460.6%
Source: XBRL data from the Viridian Therapeutics, Inc.\DE (VRDN) Q2 2026 10-Q on SEC EDGAR. USD.
Viridian Therapeutics, Inc.\DE Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Newly added debt-service risk triggered by May 2026 issuance of $250.0 million 1.75% convertible senior notes due 2032
- Most materially updated liquidity risk: $981.5 million cash, cash equivalents, and marketable securities expected to fund operations at least twelve months
- DRI milestone-financing risk: up to $130.0 million remains available but depends on elegrobart trials, regulatory approvals, or commercial sales
- Elegrobart regulatory risk: failed autoinjector bioequivalence could significantly delay or abandon its BLA and marketing approval
- Clinical-development risk: FDA or other authorities may require more than the planned 300-patient elegrobart safety database
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Viridian Therapeutics, Inc.\DE quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.